Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Lung Cancer

Free Subscription 23.11.2020 1 AJR Am J Roentgenol 5 Am J Respir Crit Care Med 1 Ann Surg Oncol 2 Ann Thorac Surg 4 BMC Cancer 1 BMJ 1 Br J Cancer 1 Cancer 3 Cancer Chemother Pharmacol 2 Cancer Res 1 Cancer Sci 3 Chest 4 Clin Cancer Res 9 Clin Lung Cancer 1 Clin Nucl Med 5 Eur J Cardiothorac Surg 2 Eur Respir J 2 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Surg Oncol 4 J Thorac Cardiovasc Surg 1 Lancet Oncol 5 Lung Cancer 1 N Engl J Med 1 Oncol Rep 1 PLoS Genet 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. GRASPARIL AD 2ND, Gottumukkala RV, Greer MC, Gee MS, et al
   Whole-Body MRI Surveillance of Cancer Predisposition Syndromes: Current Best Practice Guidelines for Use, Performance, and Interpretation.
   AJR Am J Roentgenol. 2020 Aug 18:1-10. doi: 10.2214/AJR.19.22399.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

2. TAKIMOTO T
   Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia, Induced by an Immune Checkpoint Inhibitor?
   Am J Respir Crit Care Med. 2020 Aug 17. doi: 10.1164/rccm.202005-2104.
   PubMed        
   
   
3. YAMASAKI M, Taniwaki M, Kawamoto K, Matsumoto N, et al
   Reply to: Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia, Induced by an Immune Checkpoint Inhibitor?
   Am J Respir Crit Care Med. 2020 Aug 17. doi: 10.1164/rccm.202006-2177.
   PubMed        
   
   
4. STEAGALL WK, Moss J
   Needle in the Haystack: Finding the Elusive Lymphangioleiomyomatosis Cell.
   Am J Respir Crit Care Med. 2020;202:1329-1330.
   PubMed        
   
   
5. HE H, Long Y, Frerichs I, Zhao Z, et al
   Detection of Acute Pulmonary Embolism by Electrical Impedance Tomography and Saline Bolus Injection.
   Am J Respir Crit Care Med. 2020 May 29. doi: 10.1164/rccm.202003-0554.
   PubMed        
   
   
6. JUTANT EM, Jais X, Girerd B, Savale L, et al
   Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1.
   Am J Respir Crit Care Med. 2020 May 21. doi: 10.1164/rccm.202001-0105.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

7. CHIANG XH, Hsu HH, Hsieh MS, Chang CH, et al
   Propensity-Matched Analysis Comparing Survival After Sublobar Resection and Lobectomy for cT1N0 Lung Adenocarcinoma.
   Ann Surg Oncol. 2020;27:703-715.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

8. MELVAN JN, Khullar O, Vemulapalli S, Kosinski AS, et al
   Community Size and Lung Cancer Resection Outcomes: Studying the Society of Thoracic Surgery Database.
   Ann Thorac Surg. 2020 Nov 12. pii: S0003-4975(20)31901.
   PubMed         Abstract available
   
   
9. MEDBERY RL, Fernandez FG, Kosinski AS, Tong BC, et al
   Costs Associated with Lobectomy for Lung Cancer: a novel analysis merging STS and Medicare data.
   Ann Thorac Surg. 2020 Nov 11. pii: S0003-4975(20)31896.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. HIGASHIYAMA M, Miyazaki R, Yamamoto H, Anayama T, et al
    Preoperative AminoIndex Cancer Screening (AICS) abnormalities predict postoperative recurrence in patients undergoing curative resection for non-small cell lung cancer.
    BMC Cancer. 2020;20:1100.
    PubMed         Abstract available
    
    
11. ZHAO J, Xiang C, Zhao R, Guo P, et al
    Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma.
    BMC Cancer. 2020;20:248.
    PubMed         Abstract available
    
    
12. WANG B, Wang DQ, Lin MS, Lu SP, et al
    Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy.
    BMC Cancer. 2020;20:1112.
    PubMed         Abstract available
    
    
13. CHAI M, Shi Q
    The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis.
    BMC Cancer. 2020;20:1121.
    PubMed         Abstract available
    
    

    
    BMJ

14. KLEE G, Langan EA
    Just an odd rash?
    BMJ. 2020;371:m4032.
    PubMed        
    
    

    
    Br J Cancer

15. KANG JH, Lee KH, Kim DW, Kim SW, et al
    A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
    Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01055.
    PubMed         Abstract available
    
    

    
    Cancer

16. NARAYAN AK, Gupta Y, Little BP, Shepard JO, et al
    Lung cancer screening eligibility and use with low-dose computed tomography: Results from the 2018 Behavioral Risk Factor Surveillance System cross-sectional survey.
    Cancer. 2020 Nov 18. doi: 10.1002/cncr.33322.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

17. LIU Y, Liu L, Liu L, Wang T, et al
    A phase I study investigation of metabolism, and disposition of [(14)C]-anlotinib after an oral administration in patients with advanced refractory solid tumors.
    Cancer Chemother Pharmacol. 2020;85:907-915.
    PubMed         Abstract available
    
    
18. LOMBARD A, Mistry H, Chapman SC, Gueoguieva I, et al
    Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation.
    Cancer Chemother Pharmacol. 2020;85:817-825.
    PubMed         Abstract available
    
    
19. HUIJBERTS SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, et al
    Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
    Cancer Chemother Pharmacol. 2020;85:917-930.
    PubMed         Abstract available
    
    

    
    Cancer Res

20. CHU W, Zhang X, Qi L, Fu Y, et al
    The EZH2-PHACTR2-AS1-ribosome axis induces genomic instability and promotes growth and metastasis in breast cancer.
    Cancer Res. 2020 Apr 20. pii: 0008-5472.CAN-19-3326.
    PubMed         Abstract available
    
    
21. BUI NHB, Napoli M, Davis AJ, Abbas HA, et al
    Spatiotemporal Regulation of DeltaNp63 by TGFbeta-Regulated miRNAs Is Essential for Cancer Metastasis.
    Cancer Res. 2020;80:2833-2847.
    PubMed         Abstract available
    
    

    
    Cancer Sci

22. SAKAI K, Tsuboi M, Kenmotsu H, Yamanaka T, et al
    Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
    Cancer Sci. 2020 Nov 13. doi: 10.1111/cas.14730.
    PubMed         Abstract available
    
    

    
    Chest

23. SCHWALK AJ, Ost DE, Saltijeral SN, De La Garza H, et al
    Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
    Chest. 2020 Nov 17. pii: S0012-3692(20)35151-5. doi: 10.1016/j.chest.2020.
    PubMed         Abstract available
    
    
24. SACHS E, Sartipy U, Jackson V
    Sex and survival after surgery for lung cancer: A Swedish nationwide cohort.
    Chest. 2020 Nov 17. pii: S0012-3692(20)35155-2. doi: 10.1016/j.chest.2020.
    PubMed         Abstract available
    
    
25. OSAROGIAGBON RU, Sineshaw HM, Lin CC, Jemal A, et al
    Institution-level differences in quality and outcomes of lung cancer resections in the United States.
    Chest. 2020 Nov 13. pii: S0012-3692(20)35134-5. doi: 10.1016/j.chest.2020.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

26. GIFFIN MJ, Cooke K, Lobenhofer EK, Estrada JC, et al
    AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Nov 17. pii: 1078-0432.CCR-20-2845.
    PubMed         Abstract available
    
    
27. SALAS-BENITO D, Eguren-Santamaria I, Sanmamed MF
    Senescent T-cells as a resistance mechanism to lung cancer immunotherapy.
    Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3507.
    PubMed         Abstract available
    
    
28. ZHUO M, Guan Y, Yang X, Hong L, et al
    The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Clin Cancer Res. 2020;26:892-901.
    PubMed         Abstract available
    
    
29. LIU Y, Zugazagoitia J, Ahmed FS, Henick BS, et al
    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
    Clin Cancer Res. 2020;26:970-977.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

30. RIUDAVETS M, Caramella C, Pradere P, Naltet C, et al
    Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30313.
    PubMed        
    
    
31. STENEHJEM DD, Lubinga SJ, Gupte-Singh K, Zhang Y, et al
    Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
    Clin Lung Cancer. 2020 Jul 29. pii: S1525-7304(20)30231.
    PubMed         Abstract available
    
    
32. ZHAO Y, Mao Y, He J, Gao S, et al
    Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30291.
    PubMed         Abstract available
    
    
33. YU H, Brustugun OT, Ekman S, Botling J, et al
    Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30299.
    PubMed         Abstract available
    
    
34. HE Z, Li Z, Xu S, Wu W, et al
    Prognostic Significance of Lymph Node Count Removed at Sublobar Resection in Pathologic Stage IA Non-Small-cell Lung Cancer: A Population-Based Analysis.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30295.
    PubMed         Abstract available
    
    
35. GARRANA SH, Dagogo-Jack I, Cobb R, Kuo AH, et al
    Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30314.
    PubMed         Abstract available
    
    
36. JANSEN AME, Sriram JD, Pluim D, Maas RJH, et al
    Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30303.
    PubMed        
    
    
37. MA J, Pi G, Bi J, Li Y, et al
    Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30309.
    PubMed         Abstract available
    
    
38. ASAHINA H, Tanaka K, Morita S, Maemondo M, et al
    A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Clin Lung Cancer. 2020 Oct 16. pii: S1525-7304(20)30305.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

39. XU T, Hu J, Zhang X, Cao J, et al
    A Case of Localized Malignant Peritoneal Mesothelioma Evaluated by 18F-FDG PET/CT.
    Clin Nucl Med. 2020 Jun 25. doi: 10.1097/RLU.0000000000003158.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

40. WANG Y, Qian F, Hu M, Chen Y, et al
    Clinical significance of visceral pleural and lymphovascular invasion in surgically resected adenosquamous lung cancer.
    Eur J Cardiothorac Surg. 2020 Nov 17. pii: 5983876. doi: 10.1093.
    PubMed         Abstract available
    
    
41. TRICARD J, Milad D, Chermat A, Simard S, et al
    Staged management of cardiac disease and concomitant early lung cancer: a 20-year single-center experience.
    Eur J Cardiothorac Surg. 2020 Nov 19. pii: 5990294. doi: 10.1093.
    PubMed         Abstract available
    
    
42. LAMPRIDIS S
    The role of surgery in oligometastatic non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2020 Nov 17. pii: 5983874. doi: 10.1093.
    PubMed        
    
    
43. DING Q, Shu J, Xu X, Chen Y, et al
    Clinical implications of the pattern of recurrence of pN2 non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2020 Nov 16. pii: 5983729. doi: 10.1093.
    PubMed        
    
    
44. FUJIBAYASHI Y, Ogawa H, Kitazume M, Nishikubo M, et al
    Pleural invasion, epidermal growth factor receptor mutation and carcinoembryonic antigen level affect pleural lavage cytology-positive status in non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2020 Nov 16. pii: 5983731. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Eur Respir J

45. INFANTE MV, Cardillo G
    Lung cancer screening in never-smokers: facts and remaining issues.
    Eur Respir J. 2020;56.
    PubMed        
    
    
46. VALLIERES E
    The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections.
    Eur Respir J. 2020;56.
    PubMed        
    
    

    
    Int J Cancer

47. GIRON P, Eggermont C, Noeparast A, Vandenplas H, et al
    Targeting USP13 mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in Non-Small Cell Lung Cancer.
    Int J Cancer. 2020 Nov 19. doi: 10.1002/ijc.33404.
    PubMed         Abstract available
    
    
48. JIN K, Hung RJ, Thomas S, Le Marchand L, et al
    Hormonal factors in association with lung cancer among Asian women: a pooled analysis from the International Lung Cancer Consortium.
    Int J Cancer. 2020 Nov 19. doi: 10.1002/ijc.33405.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

49. KIM YE, Gwak SH, Hong BJ, Oh JM, et al
    Effects of ultra-high dose rate FLASH irradiation on the tumor microenvironment in Lewis lung carcinoma: role of myosin light chain.
    Int J Radiat Oncol Biol Phys. 2020 Nov 10. pii: S0360-3016(20)34500.
    PubMed         Abstract available
    
    
50. XING L, Wu G, Wang L, Li J, et al
    Erlotinib vs etoposide/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: A multicenter, randomized, open-label, phase 2 trial.
    Int J Radiat Oncol Biol Phys. 2020 Nov 18. pii: S0360-3016(20)34548.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

51. ZHENG Q, Huang Y, Zeng X, Chen X, et al
    Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
    J Cancer Res Clin Oncol. 2020 Nov 16. pii: 10.1007/s00432-020-03444.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

52. ZHA P, Deng HY
    Diabetes mellitus and prognosis of non-small-cell lung cancer patients after surgery: What do we know?
    J Surg Oncol. 2020 Nov 20. doi: 10.1002/jso.26307.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

53. DE LEON LE, Bravo-Iniguez CE, Fox S, Tarascio J, et al
    Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2020;160:1064-1073.
    PubMed         Abstract available
    
    
54. MUENYI C, Ng T
    Commentary: Sublobar resection, closing in as the standard in surgical management for a subgroup of patients with lung cancer.
    J Thorac Cardiovasc Surg. 2020 Oct 17. pii: S0022-5223(20)32848.
    PubMed        
    
    
55. TSUTANI Y, Handa Y, Shimada Y, Ito H, et al
    Comparison of cancer control between segmentectomy and wedge resection in patients with clinical stage IA non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Oct 22. pii: S0022-5223(20)32833.
    PubMed         Abstract available
    
    
56. D'ANDRILLI A, Rendina EA
    Commentary: Second ipsilateral metachronous lung cancer: What to do?
    J Thorac Cardiovasc Surg. 2020 Jul 24. pii: S0022-5223(20)32224.
    PubMed        
    
    

    
    Lancet Oncol

57. GOURD E
    Lung cancer control in the UK hit badly by COVID-19 pandemic.
    Lancet Oncol. 2020 Nov 12. pii: S1470-2045(20)30691.
    PubMed        
    
    

    
    Lung Cancer

58. BISHNOI R, Shah C, Blaes A, Bian J, et al
    Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
    Lung Cancer. 2020;150:172-177.
    PubMed         Abstract available
    
    
59. JOOSTEN PJM, Dickhoff C, van der Noort V, Klomp HM, et al
    Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
    Lung Cancer. 2020;150:209-215.
    PubMed         Abstract available
    
    
60. YUN JK, Park I, Kim HR, Choi YS, et al
    Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: A propensity score-weighted comparison with open thoracotomy.
    Lung Cancer. 2020;150:201-208.
    PubMed         Abstract available
    
    
61. ZHOU Y, Wang B, Qu J, Yu F, et al
    Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2020;150:178-185.
    PubMed         Abstract available
    
    
62. ZENG J, Mao WM, Chen QX, Luo TB, et al
    Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
    Lung Cancer. 2020;150:164-171.
    PubMed         Abstract available
    
    

    
    N Engl J Med

63. SHAW AT, Bauer TM, de Marinis F, Felip E, et al
    First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    N Engl J Med. 2020;383:2018-2029.
    PubMed         Abstract available
    
    

    
    Oncol Rep

64. WANG L, Wang W
    Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in nonsmall cell lung cancer (Review).
    Oncol Rep. 2020 Nov 13. doi: 10.3892/or.2020.7851.
    PubMed         Abstract available
    
    

    
    PLoS Genet

65. MULLEN DJ, Yan C, Kang DS, Zhou B, et al
    TENET 2.0: Identification of key transcriptional regulators and enhancers in lung adenocarcinoma.
    PLoS Genet. 2020;16:e1009023.
    PubMed         Abstract available
    
    

    
    PLoS One

66. TETZLAFF F, Epping J, Golpon H, Tetzlaff J, et al
    Compression, expansion, or maybe both? Growing inequalities in lung cancer in Germany.
    PLoS One. 2020;15:e0242433.
    PubMed         Abstract available
    
    
67. YOGO N, Hase T, Kasama T, Nishiyama K, et al
    Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients.
    PLoS One. 2020;15:e0241422.
    PubMed         Abstract available
    
    
68. CHEN X, Wang L, Su X, Luo SY, et al
    Identification of potential target genes and crucial pathways in small cell lung cancer based on bioinformatic strategy and human samples.
    PLoS One. 2020;15:e0242194.
    PubMed         Abstract available
    
    
69. WANG Q, Xu L, Wang G, Chen L, et al
    Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2020;15:e0241241.
    PubMed         Abstract available
    
    
70. MORENO-BARBOSA F, de Celis-Alonso B, Moreno-Barbosa E, Hernandez-Lopez JM, et al
    Monte Carlo simulation of the effect of magnetic fields on brachytherapy dose distributions in lung tissue material.
    PLoS One. 2020;15:e0238704.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: